Canadian Society of Allergy and Clinical Immunology
La Société canadienne d’allergie et d’immunologie clinique

CSACI 2017

TORONTO, ONTARIO
October 11 TO 15
11 au 15 octobre

Preliminary program – programme préliminaire
REGISTRATION DESK HOURS

PRE-FUNCTION B

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday, October 11</td>
<td>14:00-18:00</td>
</tr>
<tr>
<td>Thursday, October 12</td>
<td>06:45-17:00</td>
</tr>
<tr>
<td>Friday, October 13</td>
<td>06:45-17:00</td>
</tr>
<tr>
<td>Saturday, October 14</td>
<td>06:45-15:30</td>
</tr>
<tr>
<td>Sunday, October 15</td>
<td>06:45-15:00</td>
</tr>
</tbody>
</table>

SHUTTLE BUSES – CSACI MEETING

BUSES WILL BE LEAVING THE ROYAL YORK STARTING ON WEDNESDAY, OCTOBER 11 AT 3:00 P.M. – AND EVERY HALF HOUR UNTIL 10:15 P.M. THAT DAY.

BUSES FOR THURSDAY, FRIDAY, SATURDAY AND SUNDAY WILL START AT 06:20 – 06:30 AND EVERY HALF HOUR UNTIL THE END OF ALL SESSIONS.

FOR MORE INFORMATION ON BUS TIMES PLEASE SEE CSACI BUS PERSON IN THE LOBBY OF THE ROYAL YORK OR AT THE BEANFIELD CENTRE.

EXHIBIT DATES AND HOURS

<table>
<thead>
<tr>
<th>Date</th>
<th>Morning</th>
<th>Lunch</th>
<th>Afternoon</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, October 12</td>
<td>10:00-12:00</td>
<td>12:00-13:00</td>
<td>14:00-1530</td>
</tr>
<tr>
<td>Friday, October 13</td>
<td>10:00-12:00</td>
<td>12:00-13:00</td>
<td>14:00-1530</td>
</tr>
<tr>
<td>Saturday, October 14</td>
<td>10:00-11:00</td>
<td>12:00-13:30</td>
<td></td>
</tr>
<tr>
<td>Sunday, October 15</td>
<td>10:00-11:00</td>
<td>12:00-13:00</td>
<td></td>
</tr>
</tbody>
</table>

Visit the Exhibits – Play the Trivia Game – and get a chance to win a (1) $600 gift certificate!

MEETING LOCATION
Beanfield Centre
Exhibition Place 105 Princes’ Blvd.
Toronto, Ontario, M6K 3C3
Welcome,

We are very proud to host our 72\textsuperscript{nd} meeting of the Canadian Society of Allergy and Clinical Immunology. This year brings together an outstanding faculty of Canadian and international speakers who will share their expertise and insights as they cover the wide spectrum of clinical and basic sciences.

As the primary Canadian gathering for the allergy community, it will provide an excellent opportunity for specialists and researchers in the field of allergy, asthma, and clinical immunology as well as allied health professionals from Canada and around the world to meet and share their knowledge in an atmosphere conducive to medical, scientific and social interaction.

Have a great meeting!

Dr. David Fischer
CSACI President

SAVE THE DATE

2018 CSACI ASM
September 12-16, 2018
Halifax Convention Centre
Halifax, Nova Scotia
2017 ANNUAL SCIENTIFIC MEETING PLANNING COMMITTEE

Dr. David Fischer, President, CPD Committee
Dr. Sandy Kapur, Past President and 2017 Program Chair
Dr. Harold Kim, CSACI Vice President
Dr. Tim Vander Leek, CSACI Treasurer
Dr. Susan Waserman, CAAIF President, OSCE Chair, CPD Committee
Dr. Lori Connors, CPD Committee Chair
Dr. Zainab Abdurrahman, NREP Co-Chair
Dr. Adele Atkinson, 2017 Program Committee
Dr. Edmond Chan, CSACI Board
Dr. Anne Ellis, FIT Bowl Chair and Abstract Co-Chair
Dr. Michael Fein, FIT Representative
Dr. Charles Frankish, 2017 Program Committee, CPD Com.
Dr. Kyla Hildebrand, Pediatrics Section Chair
Dr. Paul Keith, 2017 Program Committee
Ms. Sara Johnson, Allied Health Co-Chair
Ms. Linda Kirste, Allied Health Co-Chair
Dr. Jason Lee, Asthma Section Chair
Dr. Sean Mace, Rhinosinusitis Chair
Dr. Doug Mack, CSACI Board
Dr. Christine McCusker, CSACI Board
Dr. Andy O’Keefe, NREP Co-Chair
Dr. Stuart Turvey, Immunology Chair
Dr. Julia Upton, Anaphylaxis and Food Allergy
Dr. Hari Vliagoftis, Abstract Co-Chair

Ms. Louise Tremblay, Executive Director
Ms. Alexi Campbell, Manager

WHY YOU SHOULD ATTEND!

As the premier meeting of the allergy, asthma and immunology community, this conference provides several unique and engaging educational opportunities for the participant – such as:

- Interact with an impressive faculty of Canadian and international speakers;
- Network with colleagues across settings and disciplines;
- Translate scientific discoveries into your practice;
- Learn about policy issues that directly affect you;
- Raise questions, debate the issues, plan follow-up studies, and discuss results;
- Discuss your own research and observation;
- Meet with poster presenters to learn about their research objectives; and
- Visit a number of exhibit booths featuring products and services specifically designed for professionals in allergy, asthma and immunology.

TARGET AUDIENCE

The CSACI Annual Scientific meeting is intended for clinicians, researchers, trainees/students, and allied health professionals involved in research, treatment and management of diseases in allergy, asthma and immunology.

CSACI MISSION AND VISION STATEMENT

The mission of the Canadian Society of Allergy and Clinical Immunology is the advancement of the knowledge and practice of allergy, clinical immunology, and asthma for optimal patient care. The Society is also dedicated to improving the quality of life of people with allergies through research, advocacy, continuing professional development and public education.

EVALUATIONS

Delegates can provide feedback on Annual Meeting Sessions they attend by using the Annual Meeting app or by visiting the CSACI website.

PROGRAM OBJECTIVES

The CSACI Annual Scientific meeting’s main objectives are to provide current information about the diagnosis, treatment and management in allergy, asthma and immunology. This meeting is a setting for interdisciplinary exchange among professionals and provides an excellent opportunity for participants to interact with colleagues and experts in the field. By participating in this conference, attendees can expect to evaluate new trends, techniques, therapies and diagnostic procedures in allergy, asthma and immunology.
ANNUAL GENERAL MEETING

All CSACI members are invited to attend the CSACI and CAAIF AGMs
Friday, October 13
1045-1200
Ballroom A-B

Participants will be eligible to win a prize!

ACCREDITATION - (Section 1 & Section 3)

This event is seeking approval for an accredited group learning activity (Section 1 & Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Please refer to the final program for accredited sessions.

AMA PRA Category 1 Credit™

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at:

CERTIFICATE OF ATTENDANCE

All participating delegates will receive an email containing their “Certificate of Attendance” following the meeting.

PROGRAM CHANGES AND CANCELLATIONS

Please note: The CSACI reserves the right to substitute faculty or to cancel or reschedule sessions because of low enrollment or other unforeseen circumstances.

DISCLOSURE

Faculty and Moderator Disclosure:
Current CME guidelines state that participants in should be aware of any affiliation or financial interest that could affect the speaker’s presentation(s). Faculty and moderators have completed conflict of interest declarations and those potential conflicts will be listed in the announced at the beginning of each session.

The intent of this disclosure requirement is not to prevent a speaker with a conflict of interest from making a presentation but to make known the relationship, in advance, to the audience. It is intended that any conflict be openly identified so that with full disclosure of the facts, attendees may form their own judgments about the presentation.

In addition, all members of the annual scientific program committee have also completed their declaration and have announced at each teleconference or meeting any financial interest in commercial organizations that may have a direct or indirect interest in the subject matter of his/her presentation. A “financial interest” may include, but is not limited to, being a direct shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An “affiliation” may be holding a position on an advisory committee or some other role of benefit to a sponsoring organization.

DISCLAIMER

The material presented at this meeting represents the opinion of the speakers and not the views of the CSACI. Attendees participating in this medical education program do so with full knowledge that they waive any claim they may have against the CSACI for reliance on any information presented during these educational activities. The CSACI does not guarantee, warrant or endorse any commercial products or services.

PLEASE NOTE THAT BREAKFASTS, BREAKS AND LUNCHES WILL BE SERVED IN THE EXHIBIT AREA.
VISIT OUR 2017 SPONSORS AND EXHIBITORS

The CSACI meeting has proven to be a great opportunity for a collegial interchange of ideas and product information between physicians and our corporate partners. The exhibit area is the exclusive room for meals and breaks. The exhibiting companies and organizations will provide you with the latest information on products and services available to physicians, researchers and allied health professionals in the field of allergy/immunology. For more information on exhibiting companies and organization, please look at the Annual Meeting app.

New this year!

Want to win a Visa gift card but tired of filling out the exhibitor passport?

The CSACI Trivia Game

...stay tuned for more details.

PLEASE NOTE THIS MEETING IS FRAGRANCE FREE

APP QR CODE

Sponsored by: Stallergenes Greer
Canadian Allergy, Asthma and Immunology Foundation Gala and Auction

October 12, 2017
6:30 pm

Fairmont Royal York
100 Front Street West | Toronto, Ontario

Featuring Bruce Croxon
Founder, Round 13 Capital;
Former Dragon on Dragon’s Den

Tickets $250
Maximum tax receipt allowable

Please visit www.allergyfoundation.ca
to purchase tickets

For more information contact
613-986-5869 or info@cAAF.ca

All funds raised go directly towards
Canadian Researchers

About Us

CAAIF’s mission is to improve the health and healthcare of Canadians by advancing the quality, relevance and application of research in allergy, asthma and immunology. To date, CAAIF has awarded over one million dollars to top Canadian researchers working in these areas.

A Growing Concern

Allergies and asthma are at an all-time high, yet funding for research and clinical care is decreasing.

Three million Canadians suffer from asthma, which is the leading cause of ER visits and hospitalizations in children.

One in 13 Canadians live with food allergies and 50% of Canadian households are affected.

Families, schools, and communities struggle to deal with rising rates of allergies and asthma.

Canadian Allergy, Asthma and Immunology Foundation (CAAIF)

How to do it

Sign up when you register for the CAAIF Annual Meeting online. Registration will also be open on-site at the meeting.

Reasons to do it

Breathe fresh ocean and mountain air to start your day
Raise funds for the Canadian Allergy, Asthma and Immunology Foundation
Enjoy the camaraderie and laughter of your peers
Receive a great t-shirt in recognition of your participation

Prizes

Prizes for the fastest male/female runner/walker
Prize for the corporate team with the largest number of participants

Please join us for the third annual

CAAIF FUNDRAISING RUN/WALK

On the beautiful waterfront of Toronto

SATURDAY, OCT. 14 FROM 3–5 P.M.
CSACI SOCIAL EVENTS

The CSACI will be holding two social events that will provide you with an opportunity to connect with fellow delegates in a more relaxed environment. This includes the opening reception to be held on Friday, October 13 from 1810-1930 where Dr. David Fischer will present plaques to our corporate partners.

On the evening Saturday October 14, the CSACI Executive and Board will be hosting the CSACI dinner. Prizes will be presented for the best posters and awards to pay special homage to our speakers and exemplary CSACI members for their outstanding achievements in the allergy, asthma and immunology field.

Follow the CSACI Annual Meeting on Twitter

While you’re in Toronto, use #CSACI17 when you tweet to participate in onsite conversations & share what you’re learning with your colleagues.
WEDNESDAY, OCTOBER 11, 2017

1530-1645
ROYAL COLLEGE SPECIALTY COMMITTEE MEETING *(closed)*
Room: 201-C
Chair: Dr. Fanny Silviu-Dan

1600-1730
CAAIF BOARD MEETING *(closed)*
Room: 201-AB
Chair: Dr. Susan Waserman

1800-2100
CSACI DINNER & BOARD MEETING *(closed)*
Room: 201-AB
Chair: Dr. David Fischer

1830-2000
NREP DINNER & MEETING *(closed)*
Room: 202-A
Chairs: Dr. Zainab Abdurrahman & Dr. Andy O'Keefe

2100-2200
FIT|NREP|ALLERGEN|CSACI PROGRAM DIRECTORS NETWORKING RECEPTION
Room: 203-AB
Chair: Dr. Anne Ellis

PLEASE NOTE SESSIONS HIGHLIGHTED IN GREEN FONT ARE OF INTEREST TO ALLIED HEALTH PROFESSIONALS

THURSDAY, OCTOBER 12, 2017

0715-0800
FIT OSCE BREAKFAST & ORIENTATION
Room: 200-AB
Chairs: Dr. Michael Fein, Dr. Zainab Abdurrahman & Dr. Andy O'Keefe

0715-0800
OSCE EXAMINERS BREAKFAST & ORIENTATION
Room: 200-C
Chairs: Dr. Susan Waserman & Dr. Bill Moote

0810-1000
OSCE CONCURRENT SESSIONS
Room: 206-ABCD
Chairs: Dr. Susan Waserman & Dr. Bill Moote
THURSDAY, OCTOBER 12, 2017

1000-1200  TRAINEE CAREER DEVELOPMENT WORKSHOP  
Room: 200-C  
Chair: Dr. Harissios Vliagoftis  
Speaker: Ms. Kim Wright, Director, Communications and Knowledge Mobilization  
AllerGen NCE Inc., Hamilton, ON  
Objectives:  
- Explain the role of a clear language summary in knowledge mobilization frameworks  
- Use simple text and structure in lay writing  
- Summarize how to avoid passive voice and hidden verbs in lay writing  
- Identify and compose four sections of an AllerGen ResearchSKETCH  
- Access online resources to support clear language writing

1015-1100  PROGRAM DIRECTORS IN THE DISTRIBUTED ACADEMIC HALF DAY PROGRAMS MEETING  
Room: 206-ABCD

1015-1100  FIT WORKSHOP (restricted to Fellows-in-Training) CONTINUED  
Room: 200-AB  
Chairs: Dr. Michael Fein, Dr. Zainab Abdurrahman & Dr. Andy O’Keefe  
BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*:  

1015-1100  FOOD DESENSITIZATION AT THE MCH  
Speaker: Dr. Moshe Ben Shoshan  
Objectives*:  
- Summarize challenges regarding burden and management of food desensitization  
- Explain the premise underlying food desensitization  
- Describe the protocols used at the MCH for milk egg and peanut desensitization  
- Summarize the initial findings from the MCH milk desensitization program

1110-1200  TRANSITION TO PRACTICE  
Speakers: Dr. Zainab Abdurrahman, Dr. Andrew O’Keefe  
Objectives*:  
1. To discuss the challenges associated with transitioning from fellowship to practice  
   a. Professional aspects  
   b. Personal aspects  
   c. Community aspects  
2. Discuss the use of EMR to enhance your medical practice  
3. Discuss the various aspects of starting a practice  
   a. Licensing  
   b. Billing  
   c. Hiring (and firing) of staff  
   d. Purchasing medical equipment
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1200-1215</td>
<td>FIT LUNCH</td>
</tr>
<tr>
<td></td>
<td><strong>Room: 200-AB</strong></td>
</tr>
<tr>
<td>1215-1315</td>
<td>CAREERS IN ALLERGY/IMMUNOLOGY: PANEL DISCUSSION</td>
</tr>
<tr>
<td></td>
<td><strong>Speakers:</strong> Dr. Michael Cyr, Dr. Tracy Pitt, Dr. Natacha Tardio</td>
</tr>
<tr>
<td></td>
<td>and Dr. Susan Waserman</td>
</tr>
<tr>
<td></td>
<td><strong>Objectives</strong>*:</td>
</tr>
<tr>
<td></td>
<td>• Compare and contrast different career paths in Allergy/Immunology.</td>
</tr>
<tr>
<td></td>
<td>• Discuss how to achieve career goals.</td>
</tr>
<tr>
<td></td>
<td>• Discuss greatest challenge and greatest success in career.</td>
</tr>
<tr>
<td></td>
<td>• Formulate strategies for finding new opportunities within</td>
</tr>
<tr>
<td></td>
<td>Allergy/Immunology.</td>
</tr>
<tr>
<td>1200-1230</td>
<td>SPONSORED LUNCH BY NOVARTIS</td>
</tr>
<tr>
<td></td>
<td><strong>Ballroom B</strong></td>
</tr>
<tr>
<td>1230-1330</td>
<td>SPONSORED SPEAKER TALK BY NOVARTIS</td>
</tr>
<tr>
<td></td>
<td><strong>Moderator:</strong> Dr. Allan Becker</td>
</tr>
<tr>
<td></td>
<td><strong>Title:</strong> &quot;Asthma management in children: Are the guidelines all wrong?&quot;</td>
</tr>
<tr>
<td></td>
<td><strong>Speakers:</strong> Drs. Allan Becker and Elissa Abrams</td>
</tr>
<tr>
<td>1330-1730</td>
<td>IMMUNODEFICIENCY CANADA SYMPOSIUM ON PRIMARY IMMUNODEFICIENCY</td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Dr. Christine McCusker, McGill University and Dr. Rae Brager, McMaster University</td>
</tr>
<tr>
<td></td>
<td><strong>BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO</strong>*:</td>
</tr>
<tr>
<td>1330-1335</td>
<td>Introduction and Welcome, Richard Thompson, CEO Immunodeficiency Canada</td>
</tr>
<tr>
<td>1335-1355</td>
<td>Reflections on Newborn Screening for SCID</td>
</tr>
<tr>
<td></td>
<td><strong>Speaker:</strong> Chaim Roifman, The Hospital for Sick Children, University of Toronto, Toronto</td>
</tr>
<tr>
<td></td>
<td><strong>Objectives</strong>*:</td>
</tr>
<tr>
<td></td>
<td>2. Overview of Newborn Screening since implemented, August 2013</td>
</tr>
<tr>
<td>1335-1400</td>
<td>Discussion Period</td>
</tr>
</tbody>
</table>
IMMUNODEFICIENCY CANADA SYMPOSIUM ON PRIMARY IMMUNODEFICIENCY
CONTINUED

Chairs: Dr. Christine McCusker, McGill University and Dr. Rae Brager, McMaster University

BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*:

1400-1420 A year in review: SCID newborn screening in the Maritimes
Speaker: Beata Derfalvi, Dalhousie University, Department of Pediatrics, Halifax, NS, Canada
Objectives*:
1. Learn about the Maritime experience with newborn screening for SCID.
2. Become familiar with further investigation of a patient with a low newborn TREC count.
3. Appreciate the non-SCID conditions that may lead to an abnormally low TREC result.

1420-1425 Discussion Period

1425-1445 Diagnostic Utility of Whole Genome Sequencing in Paediatric Medicine
Speaker: Christian Marshall, The Hospital for Sick Children, Paediatric Laboratory Medicine, Toronto, ON
Objectives*:
4. Describe the basic experimental approaches and strategies for genomic sequencing
5. List and discuss the advantages and limitations of genomic sequencing
6. Understand the current and future clinical applications of genomic sequencing

1445-1450 DISCUSSION PERIOD

1450-1520 LIGHTNING TALKS
Chair: Adelle Atkinson, University of Toronto

1450-1500 Severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation is caused by mutation in the NHEJ1 gene
Hannah Roberts*, Stuart Turvey, Victoria Cook, Kyla Hildebrand
University of British Columbia, Department of Pediatrics, Vancouver, BC
Objectives*:
1. Utilize a case presentation to strengthen knowledge on NHEJ1-SCID
1330-1730 IMMUNODEFICIENCY CANADA SYMPOSIUM ON PRIMARY IMMUNODEFICIENCY CONTINUED

Ballroom B

Chairs: Dr. Christine McCusker, McGill University and Dr. Rae Brager, McMaster University

BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*:

1500-1510 Maintenance of T cell receptor excision circles (TREC) levels in zeta chain-associated protein kinase of 70 kD (ZAP70) deficiency

Sneha Suresh*, Chaim Roifman
The Hospital for Sick Children, University of Toronto, Toronto

Objectives*:
1. Describe the presumed role of ZAP70 in T cell development and activation.
2. Generate hypotheses for possible mechanisms of TREC maintenance vs. decline in ZAP70 deficiency.

1510-1520 QUESTION AND ANSWER

1520-1550 NUTRITION BREAK

1550-1600 Case of 22q11.2 Deletion Syndrome Not Identified by TBX1 Screening with a Positive SCID Newborn Screen

Amanda Ciccolini*, Lauren Brick, Elizabeth McCreary, Dennis E. Bulman, Rae Brager
McMaster Children’s Hospital, Department of Pediatrics, Hamilton

Objectives*:
1. Understand the screening process for 22q11.2 Deletion Syndrome as a component of the newborn screening for Severe Combined Immune Deficiency.
2. Recognize the limitations of the screening assay and the importance of performing definitive diagnostic testing for 22q11.2 Deletion Syndrome.
3. Appreciate the need for the development of a standardized follow-up testing algorithm across Canadian institutions for newborns who screen positive for Severe Combined Immune Deficiency.

1600-1610 Causes of False-Positives in Severe Combined Immune Deficiency Newborn Screening based on T-Cell Receptor Excision Circles (TRECs): A single Center Canadian Experience

Mohammad Alsalamah*, Sneha Suresh, Brenda Reid, Chaim Roifman
The Hospital for Sick Children, The Division of Immunology & Allergy, Toronto

Objectives*:
1. List the advantages and limitations of TREC based newborn screening for SCID
2. Describe common causes of false-positive TREC based newborn screening for SCID. The local experience at the Hospital for Sick Children will be used as an illustrative example
3. Postulate possible mechanisms of false-negativity and false-positivity of TREC based newborn screening.
1330-1730  
**Ballroom B**

**IMMUNODEFICIENCY CANADA SYMPOSIUM ON PRIMARY IMMUNODEFICIENCY CONTINUED**

Chairs: Dr. Christine McCusker, McGill University and Dr. Rae Brager, McMaster University

**BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO***:

1610-1620  
The effects of Purine Nucleodide Phosphorylase deficiency on neuronal development

Michael Tsui*, Weixian Min*, Jonathan Chan*, Jeremy Biro, Eyal Grunebaum
The Hospital for Sick Children, The Division of Immunology & Allergy, Toronto

1620-1630  
Interleukin-2 receptor common gamma chain (IL2RG) defects present a diagnostic challenge

Caroline Weisser*, Dennis E. Bulman, Kayla Flamenbaum, Maian Roifman
The Hospital for Sick Children, The University of Toronto, Toronto

Learning Objectives***:

1. Understand the complexity of genetic analysis in SCID patients and family members
2. Emphasize the importance of proper molecular diagnostic aids for family genetic counselling
3. Recognize next generation sequencing as superior to traditional methods in providing answers for family planning and counselling

1630-1640  
Coronin 1A deficiency: First Presentation as a Positive Newborn Screen for Severe Combined Immunodeficiency

Yael Dinur Schejter*, Adi Ovadia, Harjit Dadi, Chaim M. Roifman
The Hospital for Sick Children, The University of Toronto, Toronto

Learning Objectives***:

1. Acknowledge the first presentation of Coronin 1A mutation as a positive newborn screen result.
2. Discuss the clinical variability of this syndrome in the literature.
3. Discuss the ethical challenges of recommending treatment in cases diagnosed as positive newborn screen with an unclear prognostic trajectory.

1640-1650  
Question and Answer

1650-1730  
Abstract winners (presented by Christine McCusker and Richard Thompson)

Best abstract
2nd place best abstract
3rd place best abstract

1900-2200  
**CAAIF GALA TO BE HELD AT THE ROYAL YORK**
FRIDAY, OCTOBER 13, 2017

0700-0730   BREAKFAST SPONSORED BY CSL BEHRING  
Pre-function C

0730-0830   SPONSORED SPEAKER TALK – BY CSL BEHRING  
A PRACTICAL APPROACH TO THE PATIENT WITH SUSPECTED IMMUNE DEFICIENCY DISEASE  
Moderator: Dr. Stephen Betschel  
Speaker: Dr. John W. Sleasman, Professor of Pediatrics, Chief, Division of Allergy, Immunology & Pulmonary Medicine, Duke University Medical Center, Department of Pediatrics, Durham, North Carolina

0845-1025   PLENARY SESSION I – FOOD ALLERGY PART 1  
Ballroom B
Moderators: Drs. Edmond Chan & Doug Mack  
BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*:  

0845-0910 First Session:  
Title: Food Allergy & Air Travel  
Speaker: Dr. Matthew Greenhawt, Associate Professor of Pediatrics, Children’s Hospital of Colorado, University of Colorado School of Medicine, Aurora, CO  
LEARNING OBJECTIVES*:  
- Explain the potential risks of environmental exposure to peanut  
- Compare and contrast current US and Canadian policy regarding flying with a peanut allergy  
- Develop strategies to help empower patients with peanut allergy to safely fly  

0910-0920   Discussion Period

0910-0945 Second Session:  
Title: Early OIT  
Speaker: Dr. Wesley Burks, Executive Dean for the University of North Carolina School of Medicine, Chapel, NC  
LEARNING OBJECTIVES*:  
- Define the mechanism of food oral immunotherapy  
- Discuss the rationale for early introduction of oral immunotherapy for food  
- Apply findings from the literature around food oral immunotherapy
PLENARY SESSION I – FOOD ALLERGY PART 1 - CONTINUED

Moderators: Drs. Edmond Chan & Doug Mack

BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*:

0945-1010 Third Session: OIT: Clinical Experience:
Speaker: Dr. Richard Wasserman, Medical Director of Pediatric Allergy and Immunology at Medical City Children’s Hospital, Dallas, TX
Objectives*:
- Evaluate individual food allergic patients for their suitability for oral immunotherapy
- Counsel patients and parents on oral immunotherapy for food allergy

1010-1025 Discussion Period for Dr. Wasserman and Dr. Burks

1025-1050 NUTRITION & NETWORKING BREAK

1055-1200 CSACI & CAAIF AGMS

1215-1245 LUNCH SPONSORED BY CSL BEHRING

1245-1345 SPONSORED SPEAKER TALK – BY CSL BEHRING
Moderator and Speaker: Dr. Stephen Betschel
A 10-minute introduction from Dr. Stephen Betschel, Toronto, on the treatment of HAE in Canada: results of a physician survey

Title: Improving the Management of Hereditary Angioedema: More Change on the Horizon
Speaker: Dr. Mark Riedl, is Professor of Medicine and Clinical Director of the US HAEA Angioedema Center at the University of California - San Diego where he also serves as Training Program Director for Allergy-Immunology. He directs an active clinical research program at UCSD focused on angioedema and immunodeficiency conditions.
FRIDAY, OCTOBER 13, 2017

1400-1440  KEYNOTE PRESENTATION
Ballroom B
Moderators: Drs. Sandy Kapur & Lori Connors
Speaker: Dr. Derek Puddester
Title: Practical tips and strategies to promote resiliency of busy health professionals: lessons learned from physician health

BY THE END OF THIS SESSION PARTICIPANTS WILL BE ABLE TO:
Objectives:
• Define and describe health-professional health as a core competency of their practice
• Identify the linkages between health-professional health, professionalism, and improved patient care
• Apply strategies to enhance their personal and family connection, sustainability, and satisfaction

1440-1510  NUTRITION & NETWORKING BREAK
Pre-function C

1510-1650  PLENARY SESSION II – FOOD ALLERGY PART 2 & PANEL DISCUSSION
Ballroom B
Moderators: Drs. Kyla Hildebrand and Caroline Weisser

BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*:

1510-1530  First Session:
Title: Food Allergy in Schools
Speaker: Dr. Susan Waserman, Hamilton, ON
(Dr. Waserman will be presented with the Milton Gold Memorial Lectureship Award
Objectives*:
• Explain the baseline risk of an allergic reaction at school
• Discuss what we know about the effects of different interventions
• Discuss the development of a new guideline on food allergy management in schools

1530-1550  Second Session:
Title: Epinephrine Auto-injectors:
Speaker: Dr. Harold Kim, Kitchener, ON
Objectives*:
• Discuss issues around epinephrine auto-injectors and needle length
• Compare and contrast new epinephrine auto-injectors
• Explain clinical modifications to address dose and needle length in infants

1550-1600  Discussion Period
FRIDAY, OCTOBER 13, 2017

1510-1650 PLENARY SESSION II – FOOD ALLERGY PART 2 & PANEL DISCUSSION - CONTINUED
Ballroom B

Moderators: Drs. Kyla Hildebrand and Caroline Weisser
BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*:

PLENARY SESSION II – PANEL DISCUSSION
Moderators: Drs. David Fischer & Tim Vander Leek
BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*:

1600-1650 Panel discussion: LEAP Implementation in Canada:
Speakers:
Dr. Edmond Chan, Vancouver, BC – Dr. Kyla Hildebrand, Vancouver, BC –
Dr. Matthew Greenhawt*, Aurora, CO – Dr. Sandy Kapur, Halifax, NS
*Dr. Matthew Greenhawt will be presented with the Bram Rose Lectureship Award.
Objectives*:
• Review the 2017 NIAID guideline’s recommendation for which infants
  should be assessed by allergists before peanut introduction
• Examine recent data on LEAP implementation in Canada
• Reflect on current barriers to providing timely access to allergists for in-
  office peanut introduction
• Discuss integration of infant observed ingestions/oral challenges in an
  Allergy practice

1700-1800 FIT BOWL
Room: 202-AB
Chair: Dr. Anne Ellis

1810-1930 OPENING RECEPTION WITH EXHIBITORS
Pre-function C

1915-2100 CSACI AND CPS JOINT PEDIATRIC DINNER MEETING – CLOSED (by invitation only)
Room: 203-AB
0630-0710  YOGA SESSION – AT THE ROYAL YORK HOTEL - Session located in the main mezzanine - TUDOR 7 & 8

0700-0730  BREAKFAST SPONSORED BY PEDIAPHARM
Pre-function C

0730-0830  SPONSORED SPEAKER TALK BY PEDIAPHARM
Ballroom B
Moderator: Dr. Susan Waserman
Speaker: Dr. Marta Ferrer Puga, Pamplona, Spain
Title: Are antihistamines All the Same

0730-1515  ALLIED HEALTH SYMPOSIUM
Room: 202-A
Moderators: Sara Johnson, RN, CAE, PhD Student (Registered Nurse, Certified Asthma Educator - Winnipeg) and Linda Kirste, MPH, RD (Registered Dietitian (Telepractice) - Vancouver)
BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*:

06:30 - 07:10  Yoga – Royal York Hotel
07:00 - 07:30  Sponsored breakfast (Pick-up in Prefunction C)
07:30 – 07:35  AH welcome
07:45-10:20  Motivational Interviewing - Theory to practice
Speakers:
• Tim Godden (MSW); Advanced Practice Clinical Leader (APCL), Acute Care Program, Centre for Addiction and Mental Health (CAMH), Toronto
• Alexandra Andric (RN); Nicotine Dependence Clinic, Centre for Addiction and Mental Health (CAMH), Toronto
Objectives:
1. Describe the core elements of motivational interviewing (MI) as a strategy to enhance motivation and client engagement
2. Observe MI in action and learn to recognize elements of the approach, including ‘MI spirit’ and micro skills
3. Gain direct experience in practice of core MI skills and explore options for pursuing further MI learning.

10:20 - 10:45 Nutrition break (pre-function C)
10:50 - 11:30 Oral abstract presentations*
11:35 -12:30 Plenary VI -Should sibs of children with peanut allergy (PA) be screened for PA?
12:30 -13:00 Lunch Break
ALLIED HEALTH SYMPOSIUM & ABSTRACT ORAL PRESENTATION(S) - CONTINUED

13:00 - 14:00  Discussion Panel: Interprofessional Collaboration in Allergy and Clinical Immunology Practice Settings

Panelists:
Dr. Allan Becker, MD, FRCPC (Paediatric Allergist - Winnipeg)
Tracie Burke, Med, RD, RP (Registered Dietitian, Registered Psychotherapist (Eating Disorders) -Toronto)
Edson Castilho, RN, CAE (Registered Nurse, Certified Asthma Educator - Halifax)
Dr. Kyla Hildebrand, MD, FRCPC, MScCH (HPTE) (Paediatric Allergist - Vancouver)

Objective:
1. Describe the current state of inter-professional collaborative practice in allergy and clinical immunology settings
2. Determine future opportunities in inter-professional practice in support of patient-centered care / positive health outcomes.

14:05 - 15:15  Allied health poster facilitated walkabout (during Poster viewing & judging)

PLENARY SESSION III – HOT TOPICS – PART 1

Ballroom B

Moderators: Drs. Julia Upton & Jason Lee

BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*:

0845-0910  First Session:
Title: Perioperative Anaphylaxis
Speaker: Dr. Lene Heise Garvey, Associate Professor, Danish Anesthesia Allergy Centre, Hellerup, Denmark

Objectives*:
- Describe clinical presentation and differential diagnosis in perioperative hypersensitivity
- Develop an approach to the investigation of perioperative hypersensitivity and information on common and hidden allergens
- Recognize the complexity of perioperative hypersensitivity
- Recognize the potential pitfalls that should be avoided when investigating
PLENARY SESSION III – HOT TOPICS – PART 1 - CONTINUED

Moderators: Drs. Julia Upton & Jason Lee

BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*:

0910-0935  Second Session:
Title: Biologics in Asthma – Practical Approach
Speaker: Dr. Richard Leigh, Professor and Head, Department of Medicine
Cumming School of Medicine, University of Calgary, Calgary, AB
Objectives*:
  • Understand the concept of Precision Medicine in asthma
  • Appreciate the role of newer therapies in severe asthma
  • Recognize the need to phenotype patients with severe asthma to identify those best likely to respond to biological therapies

0935-1000  Third Session:
Title: Venom Allergy
Speaker: Dr. David Golden, Associate Professor of Medicine, Johns Hopkins University, Baltimore, MA
Objectives*:
  • Identify optimal diagnostic tests, risk factors for severe reactions to stings, who should get VIT, dose regimens and problems during VIT.
  • Describe the significance of serum tryptase and mastocytosis in insect sting allergy.
  • Evaluate when to discontinue VIT and risk factors for relapse.

1000-1020  Discussion Period

1020-1045  NUTRITION & NETWORKING BREAK

Pre-function C
ABSTRACT ORAL PRESENTATIONS CLINICAL

Clinical 1 (Allergic Rhinitis, Asthma and Other Allergic Conditions)

1050-1053 Helen Cai (AllerGen) Determining if asthma risk at 5 years can be predicted in early life using infant and preschool pulmonary function tests (PFTs)
1053-1056 Anil Mavi (CSACI) Quantification of specific IgE & IgG against pigeon allergens in asthmatic patient’s A Indian study
1056-1059 Garthika Navaranjan (AllerGen) Assessing Canadian children’s exposure to phthalates and polycyclic aromatic hydrocarbons (PAHs)
1059-1102 Mark Tenn (AllerGen) Comparative analysis of total ocular and total rhinoconjunctivitis symptom profiles in the Environmental Exposure Unit versus the Nasal Allergen Challenge model
1102-1105 Jenny Thiele (AllerGen) ARCIC - A Correlation Analysis of Specific IgE Levels and Skin Prick Testing with Symptoms Induced via the Nasal Allergen Challenge Model of Allergic Rhinitis
1105-1108 Jodi Valois (CSACI) An Update - The observed incidence of adverse reactions in patients receiving omalizumab therapy
1108-1111 Dhuha Al-Sajee (AllerGen) Expression profile of IL-33 in the skin of atopic dermatitis post-allergen exposure
1111-1114 John Paul Oliveria (CSACI) FoxP3+ regulatory B cells were higher in sputum and blood, but lower in bone marrow following whole lung allergen challenge in allergic asthmatics
1114-1117 Emma Price (AllerGen) The novel characterization of eosinophil progenitors in the skin of atopic dermatitis patients following intradermal allergen challenge
1117-1120 Sofianne Gabrielli (AllerGen) Diagnosis of macrolide allergy through graded oral challenge
1120-1123 Geneviève Genest (CSACI) IVIG for recurrent pregnancy loss and recurrent implantation failure: experience at the MUHC
1123-1126 Ghislaine Isabwe (CSACI) Phenotypes, endotypes and biomarkers of hypersensitivity reactions to 16 monoclonal antibodies: Management with desensitization in 104 patients
1126-1129 Raymond Mak (CSACI) Natural history, long term outcomes, and treatment response for patients with idiopathic angioedema

Clinical 2 (Food Allergy and Anaphylaxis)

1050-1053 Elaine Hsu (CSACI) Barriers to oral food challenge (OFC) implementation in Canada
1053-1056 Béatrice Paradis (CSACI) Fair prioritization of patient referrals for oral immunotherapy in a public health system
1056-1059 Noémie Paradis (CSACI) Safety of daily food introduction in food allergic children with high reaction thresholds
1059-1102 Sarah Zhabi (CSACI) Venom triggered anaphylaxis cases management and clinical characteristics in Canada
1102-1105 Sara Johnson (CSACI) The lived experience of teens with Food-Induced Anaphylaxis (FIA): a proposed study
1105-1108 Christina Huang (CSACI) Predictors of Prognosis for Chronic Idiopathic Urticaria
1108-1111 Alisha Awadia (CSACI) Usability and comprehension of an illustrated canadian anaphylaxis action plan for kids (Kids’ CAP study)
1111-1114 Jeremy Biro (CSACI) Structured school environment may protect elementary school children from food allergy reactions.
1050-1135  CONCURRENT SESSIONS:
Moderators: Drs. Anne Ellis, Harissios Vliagoftis, Elinor Simons

ABSTRACT ORAL PRESENTATIONS CLINICAL  (Room: 201-C)
Clinical 2 (Food Allergy and Anaphylaxis) - CONTINUED

1114-1117  Ana Copaescu (CSACI) Rush and ultrarush venom immunotherapy in very young children
1117-1120  Sarah De Schryver (CSACI) Safety profile of the first Canadian randomized controlled trial of oral immunotherapy with cow’s milk in children
1123-1126  Mihaela Paina (CSACI) Prevalence of peanut allergy among high-risk infants with peanut introduction before and after assessment in Pediatric Allergy Clinic
1126-1129  Juan Ruiz (CSACI) Cross Canada Anaphylaxis Registry (CCARE): Comparing the epidemiology and management of anaphylaxis in Calgary and Montreal

1140-1235  PLENERARY SESSION IV - Pro/Con: Should Siblings of Peanut Allergic Children be Screened for Peanut Allergy?
Moderators: Drs. Zainab Abdurrahman & Andy O’Keefe
BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*:

Speaker: Pro: Dr. Philippe Bégin, Assistant Professor, Université de Montréal, Montréal, QC
Objectives:
• Summarize the evidence for increased risk of anaphylaxis upon introduction of peanuts in siblings
• Discuss advantages and disadvantages of screening siblings for peanut allergy
• Recognize the patient’s perspective in sibling peanut introduction

Speaker: Con: Dr. Tim Vander Leek, Associate Clinical Professor, Department of Pediatrics, University of Alberta, Edmonton, AB
Objectives:
• Discuss the incidence of peanut sensitization and peanut allergy in an unselected atopic population
• Compare the above with the risk of clinical hypersensitivity to peanut in an sibling of a child with peanut allergy
• Discuss the psychosocial aspects of screening for peanut allergy in an infant population
SATURDAY, OCTOBER 14, 2017

1235-1300  LUNCH SPONSORED BY ALK
Pre-function C

1300-1400  SPONSORED SPEAKER TALK BY ALK
Ballroom B
Moderator: Dr. David Fischer
Speaker: Dr. Hendrik Nolte, Copenhagen, Denmark
Topic: HDM allergic rhinitis with a focus on prevalence, diagnosis and treatment options

1405-1515  POSTER VIEWING AND JUDGING SESSION
Ballroom B
Moderators: Drs. Anne Ellis, Harissios Vliagoftis, Elinor Simons

1530-1700  FREE TIME & CAAIF RUN (depart from Beanfield Centre)

1545-1645  JOURNAL MEETING (closed)
Room: 201-A

1615-1715  INDUSTRY SUMMIT – ROUNDTABLE DISCUSSION (closed)
Room: 203-A

1830-1930  CONCURRENT SESSIONS:
Moderators: Drs. Anne Ellis, Harissios Vliagoftis, Elinor Simons

CASE REPORT DISCUSSION SYMPOSIUM - Room: 202-A

1830-1833 Adil Adatia (CSACI) Hepatopulmonary syndrome secondary to possible nodular regenerative hyperplasia in a patient with common variable immunodeficiency
1833-1836 Zeyana Alhadhram (CSACI) Anaphylactic reaction to blood products
1836-1839 Joel Brooks (CSACI) The safety of etoposide phosphate administration in pediatric patients with an etoposide hypersensitivity
1839-1842 Matthew Laird (CSACI) Low dose mepolizumab in the treatment of idiopathic hypereosinophilic syndrome
1842-1845 Nicholas Campbell (CSACI) Treatment of chronic granulomatous disease-associated fistulising colitis with vedolizumab: a case report
1845-1848 Stephanie Erdle (CSACI) First-reported pediatric case of anaphylaxis to American ginseng
1848-1851 Andrew Wong-Pack (CSACI) Use of rupatadine in the management of catamenial anaphylaxis
1851-1854 Valerie Massey (CSACI) A report of a 35 year-old man newly diagnosed with familial hemophagocytic lymphohistiocytosis type 2 with absent perforin activity
1854-1857 Sanju Mishra (CSACI) Progressive myopathy with functional impairment: a potential presentation of late-onset eosinophilic myositis
1857-1900 Nazanin Montazeri (CSACI) Wide complex rhythm following intravenous epinephrine injection for venom induced anaphylaxis: a case report
1900- 1903 Safiah Sumayli (CSACI) NOD2 and NLRP3 mutation in a patient presented with chronic periodic urticaria and angioedema
SATURDAY, OCTOBER 14, 2017

1830-1930

**CONCURRENT SESSIONS:**
Moderators: Drs. Anne Ellis, Harissios Vliagoftis, Elinor Simons

**CASE REPORT DISCUSSION SYMPOSIUM – CONTINUED**  Room: 202-A

1903-1906 Yuanhang Sun (CSACI) Successful desensitization in a patient with anaphylaxis to 5% human serum albumin
1906-1909 Herman Tam (CSACI) Meningococcal sepsis in possible complement deficiency: a case report
1909-1912 Kun Tian (CSACI) An interesting case of beer allergy
1912-1915 David Yue (CSACI) A case of systemic allergic reaction to breast milk
1915-1918 Karver Zaborniak (CSACI) Subcutaneous immunoglobulin for the treatment of chronic spontaneous urticaria: a case report
1918-1921 Boyang Zhang (CSACI) Fixed drug eruption following pegylated doxorubicin administration – case report

**ABSTRACT ORAL PRESENTATION- BASIC – Room 202-B**

1830-1833 Laura Feldman (AllerGen) Assessing the performance of the Air Quality Health Index Plus (AQHI+) in detecting health services utilization for asthma and COPD in Ontario, Canada
1833-1836 Young Woong Kim (AllerGen) Immune gene signatures in blood of patients with allergic rhinitis following nasal allergen challenge
1836-1839 Diana Pham (AllerGen) The Synergistic Role of Human Rhinovirus and TGF?1 in the Pathogenesis of Airway Remodeling in Asthma
1839-1842 Matthew Rawls (AllerGen) Interleukin-4 and interleukin-13 protein and gene expression from birch allergen stimulated peripheral blood mononuclear cells before and after nasal allergen challenge
1842-1845 Nami Shrestha (AllerGen) Longitudinal Analysis of Stability of Immune and Physiological Biomarkers of Asthma
1845-1848 Bahar Torabi (AllerGen) PD-L1+ regulatory B cells increase during milk oral immunotherapy
1848-1851 Catherine Biggs (AllerGen) Characterization of an autosomal dominant immune dysregulatory syndrome caused by a JAK1 gain-of-function mutation
1851-1854 Bassel Dawod (AllerGen) Examining the impact of TLR2 and cow’s milk on oral tolerance development
1854-1857 Marylin Desjardins (AllerGen) Impaired Semaphorin 4C (Sema4C) expression in patients with common variable immunodeficiency (CVID)
1857-1900 Kurtis Ng (AllerGen) Mast cells enhance resistance against influenza A in epithelial cells
1900-1903 Mallory Gallant (AllerGen) Cytokine profile of Th1 and Th2 cells following T cell polarization in high and low atopic risk umbilical cord blood mononuclear cell samples
1903-1906 Christopher Liwski (AllerGen) The impact of IgE-mediated activation on human mast cell responses to viral infection

1900-2000  CSACI RECEPTION
Lounge D

2000-2200  CSACI DINNER AND AWARDS
Ballroom B
INTEREST SECTION BREAKOUT MEETINGS
Participants will be asked to pick up their breakfast and attend the interest section meeting of their choice

- Anaphylaxis & Food Allergy – Section Advisor: Dr. Julia Upton
  Speaker: Dr. Lene Heise Garvey (Room: 202-A)
- Immunology – Section Advisor: Dr. Stuart Turvey (Room: 202-B)
- Rhino-Sinusitis – Section Advisor: Dr. Sean Mace (Room: 201-A)
- Asthma – Section Advisor: Dr. Jason Lee (Room: 201-C)
  Speaker: Dr. David Fahmy
- Allied Health – Section Advisors: Ms. Linda Kirste & Ms. Sara Johnson (Room: 201-B)

PLENARY V – HOT TOPICS – PART 2
Ballroom B
Moderators: Drs. Richard Warrington & Michael Fein
BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*:

0840-0900 First Session: Urticaria Guidelines Update:
Speaker: Dr. Gordon Sussman, President of the Ontario Allergy, Asthma, and Immunology Society, Toronto, ON
Objectives*:
- Summarize guideline development process
- Explain guidelines for recommended investigation and monitoring of patients with urticaria
- Interpret updated urticaria treatment guidelines

0900-0920 Second Session: HAE Guidelines Update:
Speaker: Dr. Stephen Betschel, Staff Clinical Immunologist and Allergist, Division of Allergy and Clinical Immunology at St. Michaels Hospital and Division of Respirology at University Health Network Toronto, Toronto, ON
Objectives*:
- Compare and contrast treatment options for HAE
- Describe current management recommendations for HAE
- Recognize the need for Improved awareness of comprehensive care in HAE and its impact on patient care
SUNDAY, OCTOBER 15, 2017

0840-0955 PLENARY V – HOT TOPICS – PART 2 – CONTINUED

0920-0940 Third Session: Penicillin Allergy:
Speaker: Dr. Moshe Ben-Shoshan, Montréal, QC
Objectives:
- Classify adverse reactions to drugs
- Recognize the health consequences related to reported high prevalence of beta lactam allergy
- Characterize immediate and non-immediate responses to antibiotics (focus on beta-lactam group)
- Discuss tests used to confirm the presence of antibiotic allergies

0940-0955 Discussion Period

1000-1210 HANDS ON SESSIONS AND BREAK – CONCURRENT SESSIONS
Moderators: Drs. Lori Connors, Dr. Wade Watson & Victoria Cook
BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*:

1000-1210 CanMEDs Leader Role: Conflict Management
- Define best practise for conflict management
- Demonstrate use of conflict management best practises
  1000-1040: CanMEDs Leader Role: Conflict Management (Room: 204 ABC)
  1045-1125: CanMEDs Leader Role: Conflict Management (Room: 204 ABC)
  1130-1210: CanMEDs Leader Role: Conflict Management (Room: 204 ABC)

1000-1210 Second Session – Asthma devices: The how to use/how to teach for all those puffers!
- Teach patients and families how to use each of the available asthma inhalers
  1000-1040: Asthma devices: The how to use/how to teach for all those puffers! (Room: 203 AB)
  1045-1125: Asthma devices: The how to use/how to teach for all those puffers! (Room: 203 AB)
  1130-1210: Asthma devices: The how to use/how to teach for all those puffers! (Room: 203 AB)
1000-1210 HANDS ON SESSIONS AND BREAK – CONCURRENT SESSIONS - CONTINUED
Moderators: Drs. Lori Connors, Dr. Wade Watson & Victoria Cook
BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*:

CONCURRENT SESSIONS: CHOOSE ONE
1000-1210 Pediatric Allergic Emergencies: Simulation
• Manage anaphylaxis in a young pediatric patient
  1000-1040: Pediatric Allergic Emergencies: Simulation (Room: 201 ABC)
  1045-1125: Pediatric Allergic Emergencies: Simulation (Room: 201 ABC)
  1130-1210: Pediatric Allergic Emergencies: Simulation (Room: 201 ABC)

1000-1210 Adult Allergic Emergencies: Simulation
• Manage anaphylaxis in an adult patient with comorbidities
  1000-1040: Adult Allergic Emergencies: Simulation (Room: 205 ABC)
  1045-1125: Adult Allergic Emergencies: Simulation (Room: 205 ABC)
  1130-1210: Adult Allergic Emergencies: Simulation (Room: 205 ABC)

1000-1210 LESSONS LEARNED FROM BIRTH COHORTS
Ballroom B
Moderator: Dr. Harissios Vliagoftis
BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*:

1000-1010 Introduction by Dr. Vliagoftis

1010-1040
Title: Lessons for Asthma
Speaker: Dr. Allan Becker, Winnipeg, MB
• Interpret data from birth cohort research
• Describe approaches to clinical care in allergy and asthma
• Develop potential plans for research

1040-1110
Title: Food Allergy
Speaker: Dr. Elinor Simons, Winnipeg, MB
Objectives:
• To review clinical and epidemiological food allergy knowledge that has been generated from birth cohort studies
• To discuss potential pitfalls of studying food allergy in birth cohorts
1000-1210  
**Ballroom B**

**LESSONS LEARNED FROM BIRTH COHORTS - CONTINUED**  
Moderator: Dr. Harissios Vliagoftis  
BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*:  

1110-1140  
**Title:** Lessons from birth cohorts on the development and regulation of Th2 responses  
**Speaker:** Dr. Thomas Eiwegger, Toronto, ON  
**Objectives:**  
- Summarize how the immune system is supposed to mature after birth in a healthy child as compared to a child that develops an atopic disease later on.  
- Describe to which extent the environment vs. the genetic predisposition defines and modulates Th2 responses early in life?  
- Determine when the best time point for interventional approaches is based on current evidence.

1140-1200  
**DISCUSSION PERIOD**

1215-1245  
**LUNCH SPONSORED BY ARALEZ**

1245-1345  
**Ballroom B**

**SPONSORED SPEAKER TALK BY ARALEZ**  
**Moderator:** Dr. David Fischer  
**Title:** “Treating Urticaria Until It Is Gone”. The Updated Urticaria Guidelines and the Role for bilastine  
**Speakers:** Dr. Susan Waserman and Dr. Gordon Sussman
PLENARY VI – LITERATURE REVIEW

Ballroom B

Moderators: Drs. Charles Frankish & Dr. Ken Sun

BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*:

1350-1410  Basic:
Speaker: Dr. Christine McCusker, Pediatrician and allergist at the Montreal Children’s Hospital, Division Director for Pediatric Allergy, Immunology and Dermatology, Clinician Scientist and Associate Professor at McGill, Montreal, QC

Objectives:
- Summarize top advances in basic immunology in 2017
- Discuss the importance of these findings to the practice of Allergy and Immunology
- Discuss translational potential of research advances into the clinical realm

1410-1430  Pediatric:
Speaker: Dr. Wade Watson, Professor of Pediatrics, Dalhousie University, Halifax, NS

Objectives:
- Describe recent advances in pediatric allergy
- Discuss the impact of these advances on patient care

1430-1450  Adult:
Speaker: Dr. Paul Keith, Associate Professor, McMaster University, Hamilton, ON

Objectives:
- Describe the results of important adult allergy and clinical immunology papers published within the last 12 months
- Discuss the implications of new findings described in the adult allergy and clinical immunology papers published within the last 12 months

1450-1510  Discussion Period

1510-1515  CLOSING REMARKS BY CSACI PRESIDENT

Ballroom B
SAVE THE DATE!

2018 ANNUAL SCIENTIFIC MEETING

September 12 to 16, 2018
Halifax, Nova Scotia